
## Shirley H Lomeli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9740322/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New reagents for increasing ESI multiple charging of proteins and protein complexes. Journal of the American Society for Mass Spectrometry, 2010, 21, 127-131.	2.8	156
2	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell, 2021, 39, 1375-1387.e6.	16.8	78
3	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discovery, 2021, 11, 714-735.	9.4	45
4	Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100426.	6.5	28
5	Plasticity of Extrachromosomal and Intrachromosomal <i>BRAF</i> Amplifications in Overcoming Targeted Therapy Dosage Challenges. Cancer Discovery, 2022, 12, 1046-1069.	9.4	27
6	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100411.	6.5	18
7	Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer Discovery, 2022, 12, 1942-1959.	9.4	15